Composition for treating radiation-induced intestinal injury and application thereof
Through the composition of quinpimethrin, quinpiethrin, quinpiethrin and baicalin, the NF-κB and Caspase-9/-3 pathways of intestinal epithelial cells are regulated, and the problem of lack of effective treatment of radiation intestinal injury in the prior art is solved. , effectively treat radiation intestinal injury, including the relief of acute, chronic injury and ulcerative colitis.
Patent Information
- Application Number
- CN202410900995.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-05
AI Technical Summary
The lack of effective drugs for the treatment of radiation intestinal injury in the prior art has made it difficult for patients to treat, and the mechanism of radiation intestinal injury is complex, which restricts the development of new drugs.
Provided is a composition including quinpimethyl, quinpiethyl, quinpimethyl and baicalin by a specific molar ratio (eg 50:70:5:10, 1:10:0.1:0.1, 100:150:30: 50) For the treatment of radiation intestinal injury, the composition can regulate the NF-κB and Caspase-9/-3 pathways of intestinal epithelial cells, reduce inflammation and apoptosis, and alleviate intestinal damage.
This composition can significantly reduce intestinal inflammation and cell apoptosis through the effects of multiple components and multiple pathways, improve intestinal barrier function, effectively treat acute and chronic radiation intestinal injury and ulcerative colitis, reduce the level of inflammatory factors, and inhibit cells Apoptosis.
Smart Images

Figure BDA0004930464880000041 
Figure BDA0004930464880000051 
Figure BDA0004930464880000052
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a composition for treating radiation-induced intestinal injury and application thereof. Background Art
[0002] Radiation-induced intestinal injury is intestinal injury caused by radiation, which can affect the small intestine, colon and rectum. The main manifestations are abdominal pain, diarrhea, blood in the stool, etc. At present, my country is facing the problem of a large number of patients with radiation-induced intestinal injury and a lack of treatment drugs. In addition, the mechanism of radiation-induced intestinal injury is complex, which to a certain extent restricts the development of new drugs against radiation-induced intestinal injury. Therefore, developing low-toxic, effective drugs with clear mechanisms of action and formulating more reasonable treatment plans have become important strategies that need to be urgently solved in the treatment of radiation-induced intestinal injury. Summary of the invention
[0003] In order to solve the above technical problems, the purpose of the present invention is to provide a composition for treating radiation-induced intestinal injury and its application, so as to solve the problem of lack of effective drugs for treating radiation-induced intestinal injury in the prior art.
[0004] The technical solution of the present invention to solve the above technical problems is as follows: a composition for treating radiation-induced intestinal injury is provided, comprising the following components: aesculin, aesculetin, aesculetin and baicalin.
[0005] On the basis of the above technical solution, the present invention can also be improved as follows:
[0006] Furthermore, the molar ratio of aesculetin, aesculetin, aesculetin and baicalein is (1-100):(10-150):(0.1-30):(0.1-50).
[0007] The beneficial effect of adopting the above further technical solution is: adopting the above molar ratio can play a role in treating radiation-induced intestinal damage.
[0008] Furthermore, the molar ratio of aesculetin, aesculetin, aesculetin and baicalein is 50:70:5:10.
[0009] Furthermore, the molar ratio of aesculetin, aesculetin, aesculetin and baicalein is 1:10:0.1:0.1.
[0010] Furthermore, the molar ratio of aesculetin, aesculetin, aesculetin and baicalein is 100:150:30:50.
[0011] The present invention also provides application of the above-mentioned composition in preparing medicine for treating radiation-induced intestinal injury.
[0012] Further, radiation-induced intestinal injury includes acute radiation-induced intestinal injury, chronic radiation-induced intestinal injury and ulcerative colitis.
[0013] The present invention also provides a medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0014] Furthermore, the dosage form of the drug is an injection, enema preparation, powder, pill, tablet, microcapsule, soft capsule, film, ointment, tincture, granule or aerosol allowed in pharmaceutical science.
[0015] The present invention has the following beneficial effects:
[0016] 1. The present invention provides a composition for treating radiation-induced intestinal injury. The composition can improve the shedding of intestinal villi, reduce the inflammatory infiltration of intestinal epithelial cells, and maintain the intestinal barrier function through the NF-κB pathway of intestinal epithelial cells; it can reduce the apoptosis of intestinal epithelial cells and alleviate intestinal damage through the Caspase-9 / -3 pathway of intestinal epithelial cells; the radiation-induced intestinal injuries that can be treated include acute radiation-induced intestinal injury, chronic radiation-induced intestinal injury, and ulcerative colitis.
[0017] 2. The composition of the present invention can reduce intestinal villus damage, reduce infiltration of intestinal inflammatory cells, and alleviate intestinal cell apoptosis by regulating the NF-κB pathway and Caspase-9 / -3 pathway of intestinal epithelial cells, thereby alleviating intestinal damage, and thus multiple components and multiple pathways work together to treat radiation-induced intestinal injury. DETAILED DESCRIPTION
[0018] The following is a description of the principles and features of the present invention, and the examples are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the embodiments, the conditions are carried out according to normal conditions or manufacturer recommendations. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0019] Embodiment 1:
[0020] A composition for treating radiation-induced intestinal injury comprises the following components: aesculin, aesculetin, aesculetin and baicalein; the molar ratio of aesculin, aesculetin, aesculetin and baicalein is 50:70:5:10.
[0021] A medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0022] Embodiment 2:
[0023] A composition for treating radiation-induced intestinal injury comprises the following components: aesculin, aesculetin, aesculetin and baicalein; the molar ratio of aesculin, aesculetin, aesculetin and baicalein is 1:10:0.1:0.1.
[0024] A medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0025] Embodiment 3:
[0026] A composition for treating radiation-induced intestinal injury comprises the following components: aesculin, aesculetin, aesculetin and baicalein; the molar ratio of aesculin, aesculetin, aesculetin and baicalein is 100:150:30:50.
[0027] A drug for treating radiation-induced intestinal injury, comprising the above-mentioned composition for treating radiation-induced intestinal injury.
[0028] A composition for treating radiation-induced intestinal injury comprises the following components: aesculetin; the molar number of aesculetin is 70.
[0029] A medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0030] Comparative Example 2:
[0031] A composition for treating radiation-induced intestinal injury comprises the following components: aesculetin and aesculetin; the molar numbers of aesculetin and aesculetin are 50 and 70 respectively.
[0032] A medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0033] Comparative Example 3:
[0034] A composition for treating radiation-induced intestinal injury comprises the following components: aesculin, aesculetin and aesculetin; the molar numbers of aesculin, aesculetin and aesculetin are 50, 70 and 5 respectively.
[0035] A medicine for treating radiation-induced intestinal injury, comprising the above composition for treating radiation-induced intestinal injury.
[0036] Test example
[0037] 1. Evaluation of pathological damage
[0038] The compositions obtained in Example 1 (in molar amounts of 50, 70, 5, and 10, respectively) and Comparative Examples 1-3 were administered intragastrically to conduct an experiment to evaluate the pathological damage of the intestinal tissue of mice. The implementation method is as follows: the mice were divided into a normal group, a model group, and the above-mentioned four groups of medication. After X-ray irradiation, the mice were continuously administered intragastrically for 7 days; samples were collected on the 8th day, and the H&E results of the intestinal tissue of the mice are shown in Table 1.
[0039] Table 1 Chinese medicine and drug pairs alleviate intestinal pathological damage in RII mice
[0040]
[0041] Experimental results: As shown in Table 1, the H&E results of mouse intestinal tissue showed that the intestinal villi and intestinal crypt structures of mice in the normal group were intact, without villus breakage and inflammatory cell infiltration; after irradiation, the intestinal structure of mice was destroyed, inflammatory cells infiltrated, intestinal villi were broken, intestinal crypts were enlarged, the number of crypts decreased, and the Chiu's score increased; after drug treatment, the pathological damage of intestinal tissue of mice with radiation damage model was alleviated, among which the effect of fraxinusin + fraxinusin + fraxinusin + baicalin was better than that of other groups.
[0042] 2. Evaluation of Pathological Lesions
[0043] The composition of Example 1 was administered by gavage to conduct an experiment to evaluate the pathological damage of intestinal tissue in mice, and the implementation method was as follows: after X-ray irradiation, the mice were weighed every day for 8 consecutive days; the mice were divided into normal group, model group, 90 μmol / kg of fraxinusin + 126 μmol / kg of fraxinusin + 9 μmol / kg of baicalin + 18 μmol / kg of baicalin, and the low and medium doses were reduced by 2 times successively; samples were collected on the 8th day, and the H&E results of the mouse intestinal tissue are shown in Table 2.
[0044] Table 2 Villus length, crypt number and Chiu's score of mouse intestinal tissue
[0045]
[0046] ## P < 0.01 compared with the Control group; ** P < 0.01 compared with the RII group; * P<0.05 compared with RII group
[0047] Experimental results: After irradiation, the body weight of mice in the model group decreased significantly; administration of the composition at low, medium and high doses can inhibit the decrease in body weight of mice. On the 8th day, the experimental results indicated that the composition of the present invention can inhibit the weight loss of mice after irradiation.
[0048] As shown in Table 2, there was no phenomenon of villus breakage in the intestines of the mice in the normal group, and the intestinal villi and intestinal crypt structures of the mice were intact; after irradiation, the intestinal structure of the mice was destroyed, the intestinal villi were broken, the intestinal crypts were enlarged, the number of crypts was reduced, and the Chiu's score was increased; after treatment with the composition, the breakage of the villi and the enlargement of the crypts were reduced, the composition could reduce the pathological damage of the intestinal tissue of the radiation-damaged model mice, and after treatment with the composition, the atrophy of the intestinal mucosa and the shedding of the intestinal villi were significantly reduced, the inflammatory infiltration of intestinal epithelial cells was reduced, and the Chiu's score of intestinal tissue damage was reduced.
[0049] 3. Detection of inflammatory factors
[0050] On the basis of the above, intestinal samples were taken from each group of mice, and the levels of inflammatory factors (IL-6, IL-10, IL-1β, TNF-α) were detected according to the operating instructions of the ELISA kit. After irradiation, the intestinal inflammatory response of mice was an important pathological process. GraphPad Prism 8.4.0 software was used to analyze and calculate the statistics. The results are shown in Table 3.
[0051] Table 3 Levels of inflammatory factors in the intestine of mice
[0052]
[0053] ## P < 0.01 compared with the Control group; ** P < 0.01 compared with the RII group; * P<0.05 compared with RII group
[0054] As shown in Table 3, compared with the normal group, radiation can cause a significant increase in pro-inflammatory factors TNF-α, IL-1β, and IL-6, and a decrease in anti-inflammatory factor IL-10; however, administration of the composition can reduce the expression of pro-inflammatory factors and increase the expression of anti-inflammatory factors in a dose-dependent manner, indicating that the composition of the present invention can reduce the level of intestinal inflammatory factors in mice with radiation-induced intestinal injury.
[0055] 4. Detection of inflammatory factors
[0056] HIEC-6 cells were used and grouped into normal group, model group, combination group 15 μmol / L + fraxinoyl 21 μmol / L + fraxinoyl 1.5 μmol / L + baicalin 3 μmol / L, the low and medium doses were decreased by 2 times successively, after X-ray irradiation, the levels of inflammatory factors (IL-6, IL-10, IL-1β, TNF-α) were detected according to the operating instructions of ELISA kit, and the results are shown in Table 4.
[0057] Table 4 Levels of inflammatory factors in HIEC-6 cells
[0058]
[0059] ## P < 0.01 compared with the Control group; ** P < 0.01 compared with the RII group; * P<0.05 compared with RII group
[0060] As shown in Table 4, compared with the normal group, radiation causes the expression of pro-inflammatory factors TNF-α, IL-1β, and IL-6 to increase, and the expression of anti-inflammatory factor IL-10 to decrease in cells; however, after administration of the composition, the expression of pro-inflammatory factors decreases, and the expression of anti-inflammatory factors increases, which is dose-dependent. This indicates that the composition of the present invention can reduce the level of inflammatory factors in HIEC-6 cells induced by radiation.
[0061] 5. Cell Apoptosis
[0062] HIEC-6 cells were used and grouped into normal group, model group and combination group of 15 μmol / L fraxinusin + 21 μmol / L fraxinusin + 1.5 μmol / L baicalin + 3 μmol / L baicalin. The low and medium doses were decreased by 2 times successively. After X-ray irradiation, cell apoptosis was detected by TUNEL kit. Apoptosis is an important pathogenesis of radiation-induced intestinal injury. The results are shown in Table 5.
[0063] Table 5 TUNEL levels in HIEC-6 cells
[0064]
[0065]
[0066] ## P < 0.01 compared with the Control group; ** P < 0.01 compared with the RII group; * P<0.05 compared with RII group
[0067] As shown in Table 5, compared with the normal group, the apoptosis of HIEC-6 cells after irradiation increased significantly. The administration of the composition can inhibit the apoptosis of HIEC-6 cells induced by X-rays in a dose-dependent manner, indicating that the composition of the present invention can inhibit the apoptosis of HIEC-6 cells after radiation.
[0068] VI. Effects on the Expression of NF-κB Pathway Proteins
[0069] The effect of the composition of Example 1 on the expression of NF-κB pathway proteins was evaluated. The cells used in the test were normal human intestinal epithelial cells HIEC-6 (ATCC cell bank, USA), and the NF-κB inhibitor HY-18738 (MedChemExpress, USA) was used as a control. The conventional Western blot method was used for testing. The implementation method was as follows: a radiation model was established, that is, HIEC-6 cells were placed in a carbon dioxide incubator (containing 5% CO2, 37°C) and cultured in DMEM / HIGH GLUCOSE medium containing 10% fetal bovine serum. The groups were divided into: normal group (Con), model group (RII), composition group, inhibitor group (HY-18738), composition + inhibitor group (composition + HY-18738), and the composition dosage was 15 μmol / L of aesculin A + 21 μmol / L of aesculin E + 1.5 μmol / L of aesculin A + 3 μmol / L of baicalein. The inhibitor dosage was 100 μM. The cells were irradiated with 4Gy of X-rays and then given corresponding drug treatment. The results are shown in Table 6-7.
[0070] Table 6 Levels of inflammatory factors in HIEC-6 cells
[0071]
[0072] ## P < 0.01 compared with the Control group; ** P<0.01 compared with RII group
[0073] Table 7 Effects of the composition on the expression of key proteins in the NF-κB pathway
[0074]
[0075] ## P < 0.01 compared with the Control group; ** P<0.01 compared with RII group
[0076] It can be seen from Tables 6-7 that after irradiation, the phosphorylation level of P65 increased significantly, while the phosphorylation expression of P65 in the combination group, HY-18738 group and combination + HY-18738 group decreased significantly, indicating that the composition of the present invention can significantly reduce the phosphorylation level of P65, thereby alleviating inflammation of HIEC-6 intestinal epithelial cells.
[0077] VII. Effects on the Expression of Caspase-9 / -3 Pathway Proteins
[0078] The effect of the composition of Example 1 on the expression of Caspase-9 / -3 pathway proteins was evaluated. The cells used in the test were normal human intestinal epithelial cells HIEC-6 (ATCC cell bank, USA), and Caspase-9 / -3 inhibitor HY-12305 (MedChemExpress, USA) was used as a control, and the conventional Western blot method was used for testing. The implementation method is: first, a radiation model is established, that is, HIEC-6 cells are placed in a carbon dioxide incubator (containing 5% CO2, 37°C) and cultured in DMEM / HIGH GLUCOSE medium containing 10% fetal bovine serum. Normal group (Con), model group (RII), composition group, inhibitor group (HY-12305), composition + inhibitor group (composition + HY-12305), the composition dosage is 15μmol / L of aesculin A+21μmol / L of aesculin E+1.5μmol / L of aesculin A+3μmol / L of baicalein. The inhibitor dosage is 50nM. The cells were irradiated with 4 Gy of X-rays. The results are shown in Table 8.
[0079] Table 8 Effects of the composition on the expression of key proteins in the Caspase-9 / -3 pathway
[0080]
[0081] ## P < 0.01 compared with the Control group; ** P<0.01 compared with RII group
[0082] As can be seen from Table 8, after irradiation, the expressions of Caspase-9, Caspase-3, Cle-Caspase-9 and Cle-Caspase-3 were significantly increased, while the expressions of Caspase-9, Caspase-3, Cle-Caspase-9 and Cle-Caspase-3 in the combination group, HY-12305 group and combination + HY-12305 were significantly decreased, indicating that the composition of the present invention can reduce the expression of Caspase-9, Caspase-3, Cle-Caspase-9 and Cle-Caspase-3, thereby alleviating the apoptosis of HIEC-6 intestinal epithelial cells.
[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A composition for treating radiation-induced intestinal injury, characterized in that: It includes the following components: aesculetin, aesculetin, aesculetin and baicalin.
2. The composition for treating radiation-induced intestinal injury according to claim 1, characterized in that: The molar ratio of aesculetin, aesculetin, aesculetin and baicalein is (1-100): (10-150): (0.1-30): (0.1-50).
3. The composition for treating radiation-induced intestinal injury according to claim 1, characterized in that: The molar ratio of aesculetin, aesculetin, aesculetin and baicalein is 50:70:5:
10.
4. The composition for treating radiation-induced intestinal injury according to claim 1, characterized in that: The molar ratio of aesculetin, aesculetin, aesculetin and baicalein is 1: 10:0.1:0.1。 5. Use of the composition for treating radiation-induced intestinal injury according to any one of claims 1 to 4 in the preparation of a drug for treating radiation-induced intestinal injury.
6. Use of the composition for treating radiation-induced intestinal injury according to claim 5 in preparing a drug for treating radiation-induced intestinal injury, characterized in that: The radiation-induced intestinal injury includes acute radiation-induced intestinal injury, chronic radiation-induced intestinal injury and ulcerative colitis.
7. A drug for treating radiation-induced intestinal injury, characterized in that: A composition for treating radiation-induced intestinal injury comprising the composition described in any one of claims 1 to 4.
8. The drug for treating radiation-induced intestinal damage according to claim 7, characterized in that: The dosage form of the drug is injection, enema preparation, powder, pill, tablet, microcapsule, soft capsule, film, ointment, tincture, granule or aerosol allowed in pharmacy.
Citation Information
Patent Citations
Cortex fraxini, scutellaria baicalensis and coptis chinensis combinational tablet group
CN102847133A
Application of baicalein to preparation of medicines for treating and preventing ionizing radiation injury
CN110448550A
Application of fraxetin in preparation of anti-enteritis drugs
CN113143915A
